老年原发性中枢神经系统淋巴瘤治疗进展
综述老年(≥60岁)原发性中枢神经系统淋巴瘤的治疗挑战与进展。诱导治疗仍以大剂量甲氨蝶呤为基础的免疫化疗为主,目标是完全缓解;巩固策略包括大剂量化疗联合造血干细胞、非清髓化疗和全脑放疗;BTK抑制剂和来那度胺等新药为不适合化疗者提供选择,但预后仍差。
要点
- 老年患者需个体化治疗,评估体能状态、合并症及老年评估工具。
- 诱导治疗首选大剂量甲氨蝶呤为基础的免疫化疗,目标完全缓解。
- 巩固可选大剂量化疗联合造血干细胞、非清髓化疗或全脑放疗。
核心结论
- 老年原发性中枢神经系统淋巴瘤预后仍差,亟需改善该年龄组结局。
研究设计与样本
- 综述,讨论老年(≥60岁)原发性中枢神经系统淋巴瘤的治疗策略。
主要发现
- 诱导治疗仍以大剂量甲氨蝶呤为基础的免疫化疗为主,多数患者可耐受。
- 巩固策略包括大剂量化疗联合造血干细胞、非清髓化疗和全脑放疗,旨在延长缓解期和维持生活质量。
- BTK抑制剂和来那度胺等新药对不适合化疗的老年患者显示疗效。
临床怎么用
- 老年患者应结合体能状态、合并症和老年评估工具制定个体化方案。
- 诱导治疗追求完全缓解,巩固治疗可选大剂量化疗联合造血干细胞、非清髓化疗或全脑放疗。
- 不适合化疗者可考虑BTK抑制剂或来那度胺等新药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management of older individuals (≥60 years) with primary central nervous system lymphoma remains a clinical challenge. Identification of optimal therapy and delivering adequate dose intensity are two of the major issues in treating elderly patients. Premorbid performance status and comorbidities influence individualised treatment approaches and geriatric assessment tools are increasingly utilised. Optimal induction treatment remains high-dose methotrexate-based immunochemotherapy, delivery is feasible in the majority of patients and the goal of treatment remains achieving complete remission. Consolidation strategies are also relevant in the elderly, aiming to maximise duration of response and quality of life (QoL). Potential options include high-dose therapy with haematopoietic stem cell consolidation, non-myeloablative chemotherapy and whole-brain radiotherapy. Efficacy of novel agents, such as Bruton tyrosine kinase inhibitors and lenalidomide, have been reported; these represent an alternative for elderly patients unfit for chemotherapy. Prognosis remains poor, improvement of outcomes in this age group is urgently needed.
引用
- Martinez-Calle N, Isbell LK, Cwynarski K, et al. Advances in treatment of elderly primary central nervous system lymphoma. Br J Haematol. 2021. PMID: 34448202. doi:10.1111/bjh.17799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。